Detalhe da pesquisa
1.
SERCA2 regulates proinsulin processing and processing enzyme maturation in pancreatic beta cells.
Diabetologia
; 66(11): 2042-2061, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37537395
2.
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
Liver Int
; 42(6): 1278-1286, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220658
3.
Contrasting model mechanisms of alanine aminotransferase (ALT) release from damaged and necrotic hepatocytes as an example of general biomarker mechanisms.
PLoS Comput Biol
; 16(6): e1007622, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32484845
4.
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.
Ann Hepatol
; 20: 100257, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32949786
5.
Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
Bioorg Med Chem Lett
; 30(7): 126986, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32046903
6.
Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.
Bioorg Med Chem
; 28(1): 115208, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31740203
7.
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
J Viral Hepat
; 26(8): 1027-1030, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30980576
8.
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
J Viral Hepat
; 26(3): 337-349, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30421537
9.
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Hepatology
; 67(4): 1253-1260, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29152781
10.
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Hepatology
; 67(2): 514-523, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28926120
11.
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Hepatology
; 68(4): 1298-1307, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29672891
12.
Profiling of RNAs from Human Islet-Derived Exosomes in a Model of Type 1 Diabetes.
Int J Mol Sci
; 20(23)2019 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31775218
13.
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
Antimicrob Agents Chemother
; 62(10)2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30061289
14.
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Antimicrob Agents Chemother
; 62(2)2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29180522
15.
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.
Antimicrob Agents Chemother
; 62(1)2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29084747
16.
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Clin Gastroenterol Hepatol
; 16(3): 417-426, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28951228
17.
Growth and metabolic characteristics of oleaginous microalgal isolates from Nilgiri biosphere Reserve of India.
BMC Microbiol
; 18(1): 1, 2018 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29433435
18.
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
J Med Virol
; 90(1): 109-119, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28842997
19.
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.
Antimicrob Agents Chemother
; 61(5)2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28193664
20.
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Antimicrob Agents Chemother
; 60(2): 1106-13, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26643326